Preventive Angioplasty in Myocardial Infarction Trial

David Wald
Wolfson Institute of Preventive Medicine
Barts and the London Medical School

European Society of Cardiology
Amsterdam, September 1st 2013
DECLARATION OF INTEREST

- I have nothing to declare
Preventive Angioplasty in Myocardial Infarction Trial

PRAMI Trial

Randomised multicentre single-blind trial conducted in five UK cardiac centres

Randomized Trial of Preventive Angioplasty in Myocardial Infarction

David S. Wald, M.D., Joan K. Morris, Ph.D., Nicholas J. Wald, F.R.S.,
Alexander J. Chase, M.B., B.S., Ph.D., Richard J. Edwards, M.D.,
Liam O. Hughes, M.D., Colin Berry, M.B., Ch.B., Ph.D.,
and Keith G. Oldroyd, M.D., for the PRAMI Investigators*

Cardiac Death, Nonfatal MI or Refractory Angina in patients having infarct-artery PCI

Hazard Ratio 0.35 (95% CI 0.21 to 0.58), p<0.001

Risk Reduction 65%

Preventive PCI n=234
No Preventive PCI n=231
Cardiac Death, Nonfata MI or Refractory Angina in patients having infarct-artery PCI

Hazard Ratio 0.36 (95% CI 0.18 to 0.73), p=0.004

Risk Reduction 64%

Preventive PCI: n=234

No Preventive PCI: n=231
Conclusion

Substantial benefit of Preventive PCI in patients with ST elevation myocardial infarction

65% ↓ cardiac death / nonfatal MI / refractory angina
64% ↓ cardiac death / nonfatal MI